Johan L. van der Plas

A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine

Hui Jing Yu, Eva Thijssen, Emilie M.J. van Brummelen et al. · Movement Disorders · 2022 · 46 citations · Full text

First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial

Pauline Verdijk, Johan L. van der Plas, Emilie M.J. van Brummelen et al. · Vaccine · 2020 · 27 citations · Full text

Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands

Johan L. van der Plas, Vincent P. Kuiper, Wilhelmina Bagchus et al. · The Lancet Infectious Diseases · 2023 · 19 citations · Full text

Malaria, Pharmacology, Causal Chemoprophylactic Activity +5

Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study

Manon L. M. Prins, Johan L. van der Plas, Maurits F. J. M. Vissers et al. · British Journal of Clinical Pharmacology · 2022 · 10 citations · Full text